Pediatric HL trials
| Reference . | Trial acronym . | Stage . | Risk . | Treatment . | EFS . | OS . | |||
|---|---|---|---|---|---|---|---|---|---|
| Survival . | % . | Survival . | % . | ||||||
| 94 | CCG-P9426 | I, IIA, IIIA | ABVE × 4 + IFRT | 8-y | 86 | 8-y | 97 | ||
| 23 | GPOH-HD-2002 | I, IIA (treatment group 1) | OEPA × 2 (M); OPPA × 2 (F) | 3-y | 90 | 3-y | 97.9 | ||
| IIB, IIE, IIIA (treatment group 2) | OEPA × 2, COPDAC × 2 (M); OPPA × 2, COPP × 2 (F) | 3-y | 91.1 (M); 87.7 (F) | ||||||
| IIBE, IIIBE, IIIB, IV (treatment group 3) | OEPA × 2, COPDAC × 4 (M); OPPA × 2, COPP × 4 (F) | ||||||||
| 95 | CCG 5942 | IA, IB, IIA | Low | COPP/ABV × 4 ± IFRT | 10-y | 83.5 | 92.5 | ||
| 96 | IA, IB, IIA (with adverse features), IIB, III | Intermediate | COPP/ABV × 6 | 10-y (IFRT) | 91.2 | 97.1 | |||
| IV | High | COPP/ABV, CHOP, etoposide/cytarabine × 2 | 10-y (no IFRT) | 82.9 | 95.9 | ||||
| 97 | COG-AHOD0431 | IA, IIA (no bulk) | AVPC × 3 ± IFRT | 4-y | 79 | 4-y | 99.6 | ||
| 98 | Stanford, Dana-Farber, and St. Jude Consortium | IA, IIA (no bulk) | VAMP × 4 ± IFRT | 2-y | 90.8 | 2-y | 100 | ||
| 22 | P9425 | IB, IIA/IIIA1 (with large mediastinal adenopathy) or IIIA2 | Intermediate | ABVE-PC × 3 | 5-y | 84 | 5-y | 95 | |
| IIB, IIIB, IV | High | RER: IFRT SER: ABVE-PC × 2 + IFRT | |||||||
| 24 | COG-59704 | IIB/IIIB (with bulk), IV | High | BEACOPP × 4; RER (F): COPP/ABV × 4; RER (M): ABVD × 2 + IFRT; SER: BEACOPP × 4 + IFRT | 5-y | 93 | 5-y | 97 | |
| 25 | COG-AHOD0031 | IB, IA/IIA (with bulk), IIB, IIIA, IVA | ABVE-PC × 2 RER: ABVE × 2 ± IFRT; SER: ABVE-PC × 2 ± DECA × 2 + IFRT | 4-y | All 85 RER 86.9 SER 77.4 | 4-y | All 97.8 RER 98.5 SER 95.3 | ||
| 24 | AHOD0831 | IIIB, IVB | Very high | ABVE-PC × 2 RER: ABVE-PC × 2 + RT (bulk only) SER: ABVE-PC × 2 + ifosfamide/vinorelbine + ABVE-PC × 2 + RT (bulk and PET2-positive sites) | 4-y | 80.2 | 4-y | 95.9 | |
| Reference . | Trial acronym . | Stage . | Risk . | Treatment . | EFS . | OS . | |||
|---|---|---|---|---|---|---|---|---|---|
| Survival . | % . | Survival . | % . | ||||||
| 94 | CCG-P9426 | I, IIA, IIIA | ABVE × 4 + IFRT | 8-y | 86 | 8-y | 97 | ||
| 23 | GPOH-HD-2002 | I, IIA (treatment group 1) | OEPA × 2 (M); OPPA × 2 (F) | 3-y | 90 | 3-y | 97.9 | ||
| IIB, IIE, IIIA (treatment group 2) | OEPA × 2, COPDAC × 2 (M); OPPA × 2, COPP × 2 (F) | 3-y | 91.1 (M); 87.7 (F) | ||||||
| IIBE, IIIBE, IIIB, IV (treatment group 3) | OEPA × 2, COPDAC × 4 (M); OPPA × 2, COPP × 4 (F) | ||||||||
| 95 | CCG 5942 | IA, IB, IIA | Low | COPP/ABV × 4 ± IFRT | 10-y | 83.5 | 92.5 | ||
| 96 | IA, IB, IIA (with adverse features), IIB, III | Intermediate | COPP/ABV × 6 | 10-y (IFRT) | 91.2 | 97.1 | |||
| IV | High | COPP/ABV, CHOP, etoposide/cytarabine × 2 | 10-y (no IFRT) | 82.9 | 95.9 | ||||
| 97 | COG-AHOD0431 | IA, IIA (no bulk) | AVPC × 3 ± IFRT | 4-y | 79 | 4-y | 99.6 | ||
| 98 | Stanford, Dana-Farber, and St. Jude Consortium | IA, IIA (no bulk) | VAMP × 4 ± IFRT | 2-y | 90.8 | 2-y | 100 | ||
| 22 | P9425 | IB, IIA/IIIA1 (with large mediastinal adenopathy) or IIIA2 | Intermediate | ABVE-PC × 3 | 5-y | 84 | 5-y | 95 | |
| IIB, IIIB, IV | High | RER: IFRT SER: ABVE-PC × 2 + IFRT | |||||||
| 24 | COG-59704 | IIB/IIIB (with bulk), IV | High | BEACOPP × 4; RER (F): COPP/ABV × 4; RER (M): ABVD × 2 + IFRT; SER: BEACOPP × 4 + IFRT | 5-y | 93 | 5-y | 97 | |
| 25 | COG-AHOD0031 | IB, IA/IIA (with bulk), IIB, IIIA, IVA | ABVE-PC × 2 RER: ABVE × 2 ± IFRT; SER: ABVE-PC × 2 ± DECA × 2 + IFRT | 4-y | All 85 RER 86.9 SER 77.4 | 4-y | All 97.8 RER 98.5 SER 95.3 | ||
| 24 | AHOD0831 | IIIB, IVB | Very high | ABVE-PC × 2 RER: ABVE-PC × 2 + RT (bulk only) SER: ABVE-PC × 2 + ifosfamide/vinorelbine + ABVE-PC × 2 + RT (bulk and PET2-positive sites) | 4-y | 80.2 | 4-y | 95.9 | |
ABV, doxorubicin, bleomycin, and vinblastine; CCG, Children’s Oncology Group; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; COPDAC, cyclophosphamide, vincristine, prednisone, and dacarbazine; COPP, cyclophosphamide, vincristine, procarbazine, and prednisone; F, female; GPOH, German Society of Pediatric Oncology and Hematology; M, male; RER, rapid early responder; SER, slow early responder.